Literature DB >> 11177666

Rational use of inotropic therapy in heart failure.

G M Felker1, C M O'Connor.   

Abstract

Despite their theoretic appeal, agents that increase cardiac contractility (positive inotropes) have consistently been shown to increase mortality when given chronically to patients with heart failure. The routine use of inotropes as heart failure therapy in either the acute or the chronic setting is not supported by the available data. Some appropriate uses of inotropes are as temporary treatment of diuretic-refractory acute heart failure decompensations, or as a bridge to definitive treatment such as revascularization or cardiac transplantation. Although controversial, the use of inotropes as a palliative measure in the small subset of patients with truly end-stage heart failure may be appropriate. An understanding of the appropriate goals of therapy is important for both patients and physicians if rational decisions about the use of inotropes are to be made.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11177666     DOI: 10.1007/s11886-001-0035-8

Source DB:  PubMed          Journal:  Curr Cardiol Rep        ISSN: 1523-3782            Impact factor:   2.931


  34 in total

Review 1.  Inotropic infusions for chronic congestive heart failure: medical miracles or misguided medicinals?

Authors:  G A Ewy
Journal:  J Am Coll Cardiol       Date:  1999-02       Impact factor: 24.094

2.  Phosphodiesterase inhibitors in refractory heart failure: bridge to beta-blockade?

Authors:  T De Marco; K Chatterjee
Journal:  J Am Coll Cardiol       Date:  1998-05       Impact factor: 24.094

3.  Randomised study of effect of ibopamine on survival in patients with advanced severe heart failure. Second Prospective Randomised Study of Ibopamine on Mortality and Efficacy (PRIME II) Investigators.

Authors:  J R Hampton; D J van Veldhuisen; F X Kleber; A J Cowley; A Ardia; P Block; A Cortina; L Cserhalmi; F Follath; G Jensen; J Kayanakis; K I Lie; G Mancia; A M Skene
Journal:  Lancet       Date:  1997-04-05       Impact factor: 79.321

4.  Intermittent milrinone effect on long-term hemodynamic profile in patients with severe congestive heart failure.

Authors:  A Hatzizacharias; T Makris; P Krespi; F Triposkiadis; P Voyatzi; N Dalianis; M Kyriakidis
Journal:  Am Heart J       Date:  1999-08       Impact factor: 4.749

5.  Xamoterol in severe heart failure. The Xamoterol in Severe Heart Failure Study Group.

Authors: 
Journal:  Lancet       Date:  1990-07-07       Impact factor: 79.321

6.  Effect of pimobendan on exercise capacity in patients with heart failure: main results from the Pimobendan in Congestive Heart Failure (PICO) trial.

Authors:  J Lubsen; H Just; A C Hjalmarsson; D La Framboise; W J Remme; J Heinrich-Nols; J M Dumont; P Seed
Journal:  Heart       Date:  1996-09       Impact factor: 5.994

7.  Inotropes in the beta-blocker era.

Authors:  B D Lowes; M A Simon; T O Tsvetkova; M R Bristow
Journal:  Clin Cardiol       Date:  2000-03       Impact factor: 2.882

Review 8.  Parenteral inotropic support for advanced congestive heart failure.

Authors:  C V Leier; P F Binkley
Journal:  Prog Cardiovasc Dis       Date:  1998 Nov-Dec       Impact factor: 8.194

9.  A comparison of oral milrinone, digoxin, and their combination in the treatment of patients with chronic heart failure.

Authors:  R DiBianco; R Shabetai; W Kostuk; J Moran; R C Schlant; R Wright
Journal:  N Engl J Med       Date:  1989-03-16       Impact factor: 91.245

10.  Long-term benefit of dobutamine in patients with congestive cardiomyopathy.

Authors:  D V Unverferth; R D Magorien; R P Lewis; C V Leier
Journal:  Am Heart J       Date:  1980-11       Impact factor: 4.749

View more
  5 in total

Review 1.  Role of guanylate cyclase modulators in decompensated heart failure.

Authors:  Veselin Mitrovic; Adrian F Hernandez; Markus Meyer; Mihai Gheorghiade
Journal:  Heart Fail Rev       Date:  2009-12       Impact factor: 4.214

Review 2.  Pharmacokinetics and pharmacodynamics of intravenous inotropic agents.

Authors:  Lasse A Lehtonen; Saila Antila; Pertti J Pentikäinen
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

Review 3.  Use of ICS/LABA (extra-fine and non-extra-fine) in elderly asthmatics.

Authors:  Alida Benfante; Marco Basile; Salvatore Battaglia; Mario Spatafora; Nicola Scichilone
Journal:  Ther Clin Risk Manag       Date:  2016-10-14       Impact factor: 2.423

4.  Mild metabolic acidosis impairs the β-adrenergic response in isolated human failing myocardium.

Authors:  Hanna Schotola; Karl Toischer; Aron F Popov; André Renner; Jan D Schmitto; Jan Gummert; Michael Quintel; Martin Bauer; Lars S Maier; Samuel Sossalla
Journal:  Crit Care       Date:  2012-08-13       Impact factor: 9.097

5.  Continuous stroke volume estimation from aortic pressure using zero dimensional cardiovascular model: proof of concept study from porcine experiments.

Authors:  Shun Kamoi; Christopher Pretty; Paul Docherty; Dougie Squire; James Revie; Yeong Shiong Chiew; Thomas Desaive; Geoffrey M Shaw; J Geoffrey Chase
Journal:  PLoS One       Date:  2014-07-17       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.